Letter to the Editor: Re: Ratti M, Hahne JC, Toppo L, et al. Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. Ther Adv Med Oncol. 2019

Bach Ardalan

Letter to the Editor:

Re: Ratti M, Hahne JC, Toppo L, et al. Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. Ther Adv Med Oncol. 2019 Jun 4;11:1758835919853954. doi: 10.1177/1758835919853954.

I read with great interest the review article from Ratti et al., from the Hospital of Cremona in Italy, reporting the clinical applications and available data related to the use of disodium-levofolinate. The authors concluded that disodium-levofolinate has demonstrated a more favorable efficacy and toxicity profile in terms of overall response rate (ORR), progression-free survival, time to progression and occurrence of severe adverse events when compared with calcium–folinic acid. In addition, they noted that disodium-levofolinate allows for shortened treatment time, which has the benefit of decreasing the amount of resources required for administration and limiting the occurrence of catheter damage.

There has been very little change in the administration of high-dose fluorouracil (5-FU) with leucovorin in colorectal carcinoma in the United States since the publication of our phase II study in 1991 suggested that short-term infusional therapy of 5-FU certainly provides a new alternative for treatment of advanced colorectal cancer. Khapzory™ received US Food and Drug Administration approval under the 505(b)(2) regulatory pathway for therapeutic equivalents, meaning that it is therapeutically identical to other leucovorin products but is pharmaceutically differentiated as being the only sodium salt-based leucovorin (disodium levoleucovorin) approved in the United States.

Sodium-based leucovorin is compatible with 5-FU, such that both products may be combined together in the same infusion bag without the risk of calcium carbonate precipitation and potential intravenous catheter occlusion, which is included on the labels of calcium-based leucovorin products. Furthermore, in vitro and in vivo experiments conducted by Di Paolo et al. confirmed the enhanced antitumor activity and good toxicity profile of the simultaneous combination of sodium-based leucovorin and 5-FU, while the sequential combination with calcium-based leucovorin failed to potentiate 5-FU activity.

As highlighted in the review by Ratti et al., comparative results from Bleiberg et al. demonstrated an observed ORR of 55% for patients treated with calcium-based leucovorin, compared with 61% for sodium-based; median overall survival durations were 11.9 months and 22.9 months (p = 0.02), respectively and progression-free survival was 8.0 and 11.5 months. In addition, grade 3 events were 64% and 46% (p = 0.28).
Catheter occlusion may require surgical catheter removal, catheter replacement, admission or readmission to the hospital, and an increased risk of bacterial infection. Although there have not been head-to-head trials comparing the efficacy of sodium-based leucovorin over calcium-based agents, as the number of patients required to support statistical superiority would have to be too large to be feasible, the primary advantages of the sodium-based formulation, in combination with 5-FU, may be a more favorable operational and safety profile, in addition to improved convenience and a time and cost-saving method of administration. The increased volume of the combination of sodium-based levoleucovorin and 5-FU in the same infusion bag is negligible and non-prohibitive for patients. As oncologists in the United States we acknowledge that the decision to make products available for use in our practices often lies with the facility pharmacy and is based on pivotal, head-to-head trials of efficacy and safety. As noted, these large trials are not available in this patient population, but the comprehensive review by Ratti et al., and smaller published studies, provide compelling evidence that sodium-based levoleucovorin is therapeutically equivalent, can be administered safely as a single infusion with 5-FU with no crystallization, and has a more favorable efficacy and toxicity profile than calcium-based leucovorin, providing an important treatment option for patients with colorectal cancer.

Bach Ardalan, MD
Professor, Sylvester Comprehensive Cancer Center
University of Miami
Email: bardalan@med.miami.edu

Conflict of interest statement
The authors declare that there is no conflict of interest.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

References
1. Ratti M, Hahne JC, Toppo L, et al. Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. Ther Adv Med Oncol 2019; 11: 1758835919853954.
2. Ardalan B, Chua L, Tian EM, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991; 9: 625–630.
3. Bruch HR and Esser M. Catheter occlusion by calcium carbonate during simultaneous infusion of 5-FU and calcium folinate. Onkologie 2003; 26: 469–472.
4. Di Paolo A, Orlandi P, Di Desidero T, et al. Simultaneous, but not consecutive, combination with folinate salts potentiates 5-fluorouracil antitumor activity in vitro and in vivo. Oncol Res 2017; 25: 1129–1140.
5. Bleiberg H, Vandebroek A, Deleu I, et al. A phase II randomized study of combined infusional leucovorin sodium and 5-FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. Acta Gastroenterol Belg 2012; 75: 14–21.
6. Ernst FR, Chen E, Lipkin C, et al. Comparison of hospital stay, costs, and readmission of alteplase versus catheter replacement among patients with occluded central venous catheters. J Hosp Med 2014; 9: 490–496.
7. Hartung G, Hofheinz RD, Wein A, et al. Phase II Study of a weekly 24 hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer. Onkologie 2001; 24: 457–462.